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A B S T R A C T
US-guided fine needle aspiration cytology is currently the best diagnostic tool for thyroid nodules. However, it is not
sensitive and specific enough for differentiating between benign and malignant follicular tumors. A potentially useful
marker for this differentiation is the PAX8-PPARg rearrangement, identified in follicular thyroid carcinomas, but not in
follicular adenomas or other types of thyroid tumors. The aim of this research was to determine the clinical significance
of the PAX8-PPARg oncogene in diagnostics follicular thyroid tumors. The study included 62 patients with follicular or
Hürthle cell tumors. Gene expression was determined by reverse transcription-polymerase chain reaction (RT-PCR) from
paraffin embedded tissues, and PCR products were checked using the agarose gel electrophoresis. The immunohistoche-
mical analysis was performed on archive paraffin embedded tissues with the monoclonal PPARã antibody. The statistical
analysis has indicated that neither the expression of PAX8-PPARg mRNA, nor the immunohystochemical analysis with
the PPARg antibody correlate with the patohystological diagnosis. The oncogene PAX8-PPARg has not met the expecta-
tions as a reliable tumor marker for differentiation between benign and malignant thyroid tumors, which makes the only
reliable histological criteria – capsular and vascular invasion.
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Introduction
According to the 2004 World Health Organization
classification of thyroid tumors, they occur as carcinoma,
adenomas and related tumors, and other thyroid tumors1.
Whereas for most thyroid tumors there are clear cyto-
logical criteria, the boundaries between adenomatoid
nodule, a follicular adenoma and well differentiated folli-
cular carcinoma are not cytologically well defined. It is
therefore necessary to find clinically reliable tumor mar-
kers which would make this differentiation possible and
thus reduce the number of unnecessarily surgeries2–5.
The most common mutations of follicular carcinomas
include RAS mutations and PAX8-PPARg rearrange-
ment, chromosomal translocation between the thyroid
transcription factor PAX8 and the nuclear receptor pero-
xisome proliferator-activated receptor g (PPARg). PAX8-
-PPARg was, et first, thought to be restricted to FCa
(Kroll et al., 2000)6, but other groups have detected the
expresion of PAX8-PPARg gene not only in FCa but also
in follicular thyroid adenomas7–13. In the present study,
we report the analysis of PAX8-PPARg gene in a series of
follicular thyroid tumors, as well as immunohistoche-
mical analysis with PPARg antibody.
Methods
The research included 62 patients with cytologically di-
agnosed follicular or Hürthle cell tumors, histologically ver-
ified as follicular or Hürthle cell adenomas or carcinomas.
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Gene expression was determined by reverse tran-
scription-polymerase chain reaction (RT-PCR). Total mRNA
was isolated from paraffin embedded tissues using High
Pure RNA Paraffin Kit (Roche Applied Science, EU) and
translated into cDNA by reverse transcriptase PCR (Su-
perscript II RT, Invitrogen, EU). PAX8-PPARã rearran-
gements were detected by PCR using one reverse (PAX8-
-R) and three forward pairs of primers (PAX8-7, PAX8-8
and PAX8-9). The nucleotide sequence of the primers
was based on the mRNA sequences deposited in Gen-
Bank. Human hypoxanthine phosphorybosyl-transferase
1 (hHPRT1) was used as a referent housekeeping gene.
Products of PCR reactions were separated by 1% agarose
gel electrophoresis and analyzed. A 362-bp amplification
band corresponds to the presence of exons 7, 8 and 9 of
the PAX8 gene, a 173-bp band corresponds to PAX8
exons 7 and 9 and a 68-bp band is the result of the fusion
between PAX8 exson 7 and exon 1 of PPARg.
Immunohistochemistry was performed on formalin-
-fixed paraffin-embedded sections attached to silanized
slides. Microwave antigen retrieval was performed at 95
°C for 30 minutes in 10-mM citrate buffer (pH 6.0). Slides
were incubated with PPARg monoclonal antibody E8
(SC-7273P, 1:100, Santa Cruz, CA, USA) for 60 minutes
on a DAKO Autostainer. The Universal DAKO LSAB-
-Plus Kit detection system (avidin-biotin complex) and
DAB chromogen (DAKO) were used according to manu-
facturer’s protocol for immune complex detection. Sec-
tions were counterstained with Mayer’s haematoxylin,
dehydrated and mounted. A tumor with PAX8-PPARg re-
arrangement detected by RT-PCR was used as a positive
control. Nuclear staining was scored as none (0), weak
(1+), moderate (2+), or strong (3+)
The statistical analysis was conducted using the SPSS
9.0, and included the analysis of categorical variables
(2x2 and RxC contingency tables), as well as the analysis
of correlation and variance14–16.
Results
Detection of the PAX8-PPARg rearrangement
RT-PCR method has proven the expression of PAX8-
-PPARg mRNA in 33% of follicular carcinomas, 14% of
Hürthle cell carcinoma, but also in 33% of follicular and
19% of Hürthle cell adenoma (Figure 1). Therefore, nei-
ther individually nor globally (steam comparison of indi-
vidual categories) there is no differences in expression
PAX8-PPARg mRNA among the analyzed histologic cate-
gories p=0.631, Freeman-Halton exact test, Table 1).
Furthermore, there is no difference in expression be-
tween different cytological categories (p=0.281, Fisher
exact test), or between adenomas and carcinomas (p=
0.177, Fisher exact test).
Immunohistochemistry
Immunohistochemical staining with PPARg antibod-
ies revealed medium and strong positive results in 3/16
follicular adenomas (18%), 3/18 follicular carcinomas
(17%), 1/15 Hürthle cell adenomas (7%), 2/13 Hürthle
cell carcinomas (15%) (Figure 2). Contingency table anal-
ysis has shown that there are no differences in PAX8-
-PPARg expression, neither globally nor in individually-
-paired comparisons of individual categories, between
the analyzed histological (global p=0.911, Freeman-Hal-
ton exact test, Table 2) and cytological categories (global
p=0.926, Freeman-Halton exact test).
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TABLE 1
ANALYSIS OF PAX8-PPARg mRNA EXSPRESSION IN PARAFFIN
EMBEDDED TISSUES
PAX8-PPARg FAd FCa HAd HCa
– 9 11 11 10
+ 7 7 4 3
p=0.631, Freeman-Halton exact test; FAd – follicular adenoma,
FCa – follicular carcinoma, HAd – Hürthle adenoma, HCa –
Hürthle carcinoma
Fig. 1. RT-PCR analysis of thyroid tumors. 362 bp› presence of exons 7, 8 and 9 of the PAX8 gene; 68 bp› fusion between PAX8 exon 7 and
exon 1 of PPARg.
Fig. 2. Immunohistochemical staining with PPARg antibodie;
strong nuclear staining (3+).
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Moreover, adenomas and carcinomas do not differ
concerning the PAX8-PPARg immunopositivity (p= 0.501,
Freeman-Halton exact test).
Discussion and Conclusion
This research included 62 patients with cytologically
diagnosed follicular (34 patients) or Hürthle cell tumors
(28 patients). Histologically, we have confirmed 16 folli-
cular adenomas, 18 follicular carcinomas, 15 Hürthle cell
adenomas and 13 Hürthle cell carcinomas.
As is well known, cytologic diagnosis has its limita-
tions and the cytologycal criteria are unable to distin-
guish follicular lesions on smears.
Searching for a better diagnostic indicator and para-
meter which could be reliable in differentiating between
malignant and non-malignant changes in the thyroid tis-
sue, Kroll et al. in 2000. described the translocation of
the PAX8 and PPARg gene [t(2;3)(q13;p25)], chimeric
oncogene PAX8-PPARg, responsible for follicular onco-
genesis. As it was found only in follicular carcinomas,
and not in follicular adenomas, papillary carcinomas and
nodular hyperplasia, the authors indicated it could be a
potentially useful marker for distinguishing malignant
and benign follicular tumors. Immunohistochemical stai-
ning with PPARg antibodies showed that all tumors for
which the presence of PAX8-PPARg gene was found us-
ing RT-PCR, show strong and diffuse positivity of the nu-
cleus to PPARg6.
Many authors have only partially confirmed the re-
search results described above. In 2002 Nikoforova et al.
found PAX8-PPARg gene in 53% of follicular carcinomas,
but also in 8% of follicular adenomas8. According to their
research, follicular carcinomas in which this gene was
isolated are highly invasive, as opposed to minimally in-
vasive PAX8-PPARg negative carcinomas. In 2002, Mar-
ques et al.9 isolated PAX8-PPARg in 56% carcinomas, but
also in 13% follicular adenomas. This translocation was
not found for papillary and anaplastic carcinomas, or in
nodular hyperplasia, so the authors consider this marker
to be specific for follicular tumors, but not reliable enough
to differentiate between carcinomas and adenomas. Sim-
ilar conclusion was made by Cheung et al. in 2003, who
found the PAX8-PPARg oncogene in 35% follicular carci-
nomas, and in as many as 55% of follicular adenomas10.
Hibi et al. have analysed the expression of PAX8-
-PPARg gene in Japanese with nodular thyroid changes.
They explain the negative findings in follicular adeno-
mas and carcinomas, papillary carcinomas, nodular hy-
perplasia, and in normal thyroid tissue by a likely ethnic-
-based tendency for translocation17.
The expression of PAX8-PPARg gene results in the in-
creased synthesis of PPARg protein. In most studies cited
above, immunohistochemical staining using PPARg anti-
body was also conducted. In PAX8-PPARg positive tu-
mors was found strong positivity of the nucleus to PPARg
antibodies6,18. Light and medium positivity of the nu-
cleus and cytoplasm is found in adenomas, non-tumour
changes, and in normal thyroid tissue. In 2005 Sahin et
al. analysed a group of 108 patients with hystologically
determined follicular tumors and performed the immu-
nohistochemical staining using PPARg antibody in order
to determine the value of immunohistochemistry as an
alternative RT-PCR method to distinguisn between ade-
nomas and carcinomas. They found the immunoposi-
tivity in 57% follicular carcinomas, 4% Hurthle cell carci-
nomas, and in 13% follicular adenomas, and concluded
that this method is useful in distinguishing between
these diseases. Moreover, according to the clinical find-
ings they collected, they state that there is a better prog-
nosis for patients with immunupositivity to PPARg anti-
body19. Most authors state the opposite, stressing a more
frequent vascular invastion and worse long-term progno-
sis for patients with PAX8-PPARg7,14,22.
In this research we used the method of polymerase
chain reaction with reverse transcription to determine
the expression of PAX8-PPARg mRNA from paraffin em-
bedded tissues in 62 patients with cytologically and hys-
tologically verified follicular or Hürthle cell carcinomas.
RT-PCR method has proven the expression of PAX8-
-PPARg mRNA in 33% of follicular carcinoma, 14% of
Hürthle cell carcinoma, but also in 33% of follicular and
19% of Hürthle cell adenoma. Therefore, neither individ-
ually nor globally (steam comparison of individual cate-
gories) there is no differences in expression PAX8-PPARg
mRNA among the analyzed histological categories. Simi-
larly, adenomas and carcinomas do not differ regarding
the expression of mRNA. These findings support the re-
sults reported in the studies discussed above9,10,23,24.
Immunohistochemical staining with PPARg antibody
in archive paraffin embedded tissues revealed medium
and strong positivity in 18% follicular adenomas, 17%
follicular carcinomas, 7% Hürthle cell adenomas, and in
15% Hürthle cell carcinomas. Contingency table analysis
has shown that there are no differences in PAX8-PPARg
expression, neither globally nor in individually-paired
comparisons of individual categories, between the ana-
lyzed histological and cytological categories. Moreover,
adenomas and carcinomas do not differ concerning the
PAX8-PPARg immunopositivity.
The comparison of the PAX-PPARg gene expression
and immunohistochemical positivity showed no statisti-
cal significance.
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TABLE 2
IMMUNOHISTOCHEMICAL ANALYSIS OF PAX8-PPARg






0 1 2 3
Follicular adenoma 16 12 1 1 2
Follicular carcinoma 18 12 3 1 2
Hürthle cell adenoma 15 13 1 0 1
Hürthle cell carcinoma 13 8 3 1 1
none (0), weak (1+), moderate (2+), strong (3+)
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This investigation has shown that the expression of
PAX8-PPARg mRNA, as well as the immunohistoche-
mical positivity do not correlate with pathohistological
diagnosis.
The aim of these study was to determine the value of
the PAX8-PPARg oncogene in differentiating between
follicular adenoma and carcinoma. Its relation to folli-
cular thyroid tumors is undoubtedly proven, but our re-
sults do not confirm the value of this oncogene as a reli-
able marker for distinguishing these tumors. Therefore,
it is questionable whether all patients with cytologically
diagnosed follicular tumors may avoid surgery.
Preliminary studies on the significance of PAX8-PPARg
gene for differentiating between follicular tumors were
conducted on a small number of patients. To confirm the
significance of this oncogene as a prognostic factor for
tyhroid tumors further studies and larger samples are re-
quired.
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ONKOGEN PAX8-PPARã U FOLIKULARNIM TUMORIMA [TITNJA^E – RT-PCR I
IMUNOHISTOKEMIJSKA ANALIZA
S A @ E T A K
Ciljana citolo{ka punkcija pod kontrolom ultrazvuka metoda je izbora u u dijagnostici ~vorastih promjena, no nedo-
voljno osjetljiva i specifi~na za razlikovanje benignih i malignih folikularnih tumora. Potencijalno koristan marker za
njihovu diferencijaciju je onkogen PAX8-PPARã, identificiran kod folikularnog karcinoma, a ne kod folikularnog adeno-
ma ni drugih tumora {titnja~e. Cilj ovog istra`ivanja je odre|ivanje klini~kog zna~aja PAX8-PPARã gena u dijagnostici
folikularnih tumora {titnja~e. U istra`ivanje su uklju~ena 62 ispitanika s folikularnim ili Hürthleovim tumorom. Eks-
presija gena je odre|ena metodom lan~ane reakcije polimeraze s obrnutom transkripcijom (RT-PCR) iz parafinskih
rezova, a PCR produkti provjereni elektroforezom na agaroznom gelu. Na arhivskim parafinskim rezovima je izvr{eno
imunohistokemijsko bojanje monoklonalnim protutijelom PPARã. Ekspresija PAX8-PPARg mRNA, kao ni imunohisto-
kemijska analiza PPARg protutijelom ne korelira s patohistolo{kom dijagnozom. Onkogen PAX8-PPARg nije opravdao
o~ekivanja u smislu pouzdanog tumorskog markera koji bi omogu}io diferencijaciju benignih i malignih tumora {tit-
nja~e, te je i dalje jedino pouzdan histolo{ki kriterij – proboj kapsule i vaskularna.
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